[go: up one dir, main page]

NL301340I2 - tisotumab vedotin - Google Patents

tisotumab vedotin

Info

Publication number
NL301340I2
NL301340I2 NL301340C NL301340C NL301340I2 NL 301340 I2 NL301340 I2 NL 301340I2 NL 301340 C NL301340 C NL 301340C NL 301340 C NL301340 C NL 301340C NL 301340 I2 NL301340 I2 NL 301340I2
Authority
NL
Netherlands
Prior art keywords
tisotumab vedotin
tisotumab
vedotin
Prior art date
Application number
NL301340C
Other languages
English (en)
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of NL301340I2 publication Critical patent/NL301340I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Invalid Beds And Related Equipment (AREA)
NL301340C 2010-06-15 2025-08-27 tisotumab vedotin NL301340I2 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35497010P 2010-06-15 2010-06-15
DKPA201000529 2010-06-15
US201161434776P 2011-01-20 2011-01-20
DKPA201100039 2011-01-20
PCT/EP2011/059917 WO2011157741A2 (en) 2010-06-15 2011-06-15 Human antibody drug conjugates against tissue factor

Publications (1)

Publication Number Publication Date
NL301340I2 true NL301340I2 (nl) 2025-10-02

Family

ID=44534293

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301340C NL301340I2 (nl) 2010-06-15 2025-08-27 tisotumab vedotin

Country Status (28)

Country Link
US (6) US9168314B2 (nl)
EP (3) EP2582728B1 (nl)
JP (1) JP6055404B2 (nl)
KR (1) KR101935058B1 (nl)
CN (3) CN103119065B (nl)
AU (1) AU2011267106B2 (nl)
BR (1) BR112012031727B1 (nl)
CA (1) CA2802782C (nl)
CY (1) CY1119616T1 (nl)
DK (1) DK2582728T3 (nl)
EA (1) EA034675B1 (nl)
ES (1) ES2647388T3 (nl)
FI (1) FIC20253007I1 (nl)
FR (1) FR25C1032I1 (nl)
HR (1) HRP20171789T1 (nl)
HU (2) HUE035599T2 (nl)
LT (2) LT2582728T (nl)
ME (1) ME02919B (nl)
MX (1) MX347893B (nl)
NL (1) NL301340I2 (nl)
NO (2) NO2582728T3 (nl)
NZ (1) NZ604718A (nl)
PL (1) PL2582728T3 (nl)
PT (1) PT2582728T (nl)
RS (1) RS56599B1 (nl)
SI (1) SI2582728T1 (nl)
SM (1) SMT201700547T1 (nl)
WO (1) WO2011157741A2 (nl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401136T3 (es) * 2002-11-15 2013-04-17 Genmab A/S Anticuerpos monoclonales humanos contra CD25
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CA2802782C (en) * 2010-06-15 2018-03-13 Genmab A/S Human antibody drug conjugates against tissue factor
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
EA201500741A1 (ru) 2013-01-10 2016-01-29 Генмаб Б.В. ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
CN103342752B (zh) * 2013-05-16 2014-07-09 太原博奥特生物技术有限公司 一种抗人组织因子单链抗体及其制备方法
EP4420729A3 (en) * 2013-11-21 2024-10-30 Genmab A/S Antibody-drug conjugate formulation
CA2937034A1 (en) * 2014-02-03 2015-08-06 National Cancer Center Anti-tissue factor monoclonal antibody
KR20220025946A (ko) * 2014-03-21 2022-03-03 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
MX2016012258A (es) * 2014-04-08 2017-01-06 Seattle Genetics Inc Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19.
CA2929542A1 (en) * 2015-05-13 2016-11-13 Pfizer Inc. Treatment with anti-efna4 antibody-drug conjugates
HUE061408T2 (hu) 2015-06-29 2023-06-28 Daiichi Sankyo Co Ltd Eljárás antitest-gyógyszer konjugátum szelektív elõállítására
KR20180034518A (ko) * 2015-07-22 2018-04-04 아이코닉 테라퓨틱스, 인코포레이티드 혈관신생 및 신혈관형성 관련 장애를 치료하는 방법
WO2017028823A1 (zh) * 2015-08-20 2017-02-23 复旦大学 靶向于组织因子的抗体、其制备方法和用途
EP3347054B1 (en) * 2015-09-11 2021-05-05 Genmab A/S Dosing regimens for anti-tf-antibody drug-conjugates
CN114191428B (zh) 2016-03-02 2024-09-24 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
WO2017158436A1 (en) * 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
EP3502141A4 (en) * 2016-08-22 2020-04-08 Fudan University ANTIBODIES TAKEN AGAINST THE TISSUE FACTOR, MANUFACTURING METHODS THEREFOR AND USE THEREOF
CN106938051B (zh) * 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
WO2018083126A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
SG11201906414VA (en) * 2017-01-24 2019-08-27 Pfizer Calicheamicin derivatives and antibody drug conjugates thereof
CN110945021B (zh) 2017-02-10 2025-09-12 根马布私人有限公司 多肽变体及其用途
CN108570106B (zh) * 2017-03-10 2021-07-16 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
SG11202003713TA (en) * 2017-11-02 2020-05-28 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP3717069A1 (en) * 2017-11-27 2020-10-07 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
MX2020007077A (es) * 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
EP3743440A1 (en) 2018-01-24 2020-12-02 Genmab B.V. Polypeptide variants and uses thereof
EP3762032A4 (en) * 2018-03-07 2021-12-22 Genmab A/S DRUG AND ANTIBODY ANTI-TISSUE FACTOR CONJUGATES, AND THEIR USE IN THE TREATMENT OF CANCER
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
MA52485A (fr) 2018-05-03 2021-03-10 Genmab Bv Combinaisons de variants d'anticorps et utilisations associées
SG11202010993VA (en) 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
MX2020011176A (es) * 2018-05-07 2020-11-12 Genmab As Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
MX2021001058A (es) * 2018-08-16 2021-04-12 Genmab As Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer.
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US12264197B2 (en) 2019-03-11 2025-04-01 Janssen Biotech, Inc. Anti-Vβ17/anti-CD123 bispecific antibodies
JP7709636B2 (ja) * 2019-07-03 2025-07-17 エクセリクシス インコーポレイテッド 抗組織因子抗体－薬物コンジュゲート及び関連方法
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof
TW202132343A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
CA3165475A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
KR20230028492A (ko) 2020-06-29 2023-02-28 젠맵 에이/에스 항-조직 인자 항체-약물 접합체 및 암의 치료에서의 그의 용도
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
US12448449B2 (en) * 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
CA3200974A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination therapy
CN113368232B (zh) * 2021-06-02 2022-08-26 上海交通大学 多特异性抗原结合蛋白及其应用
CA3227357A1 (en) * 2021-07-29 2023-02-02 Eun Ji Shin Hemocompatible mesenchymal stem cells, preparation method therefor and use thereof
CA3244292A1 (en) 2022-02-24 2025-04-29 Evopoint Biosciences Co., Ltd. ANTIBODIES, DRUG CONJUGATES AND THEIR USES
TW202408583A (zh) 2022-05-06 2024-03-01 丹麥商珍美寶股份有限公司 使用抗組織因子抗體－藥物共軛體以治療癌症之方法
IL319963A (en) * 2022-10-19 2025-05-01 Multitude Therapeutics Inc Antibodies, antibody-drug conjugates, compositions and uses thereof
CN118772282A (zh) * 2023-04-10 2024-10-15 复旦大学 靶向组织因子的纳米抗体及偶联物的制备方法和用途
EP4506015A1 (en) 2023-08-09 2025-02-12 Nerviano Medical Sciences S.r.l. Combination of a mps1 inhibitor and an antibody drug conjugate
WO2025081117A2 (en) * 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US505731A (en) 1893-09-26 Ice oeeam feeezee
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991001754A1 (en) 1989-08-09 1991-02-21 Rhodes Buck A Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0505500B1 (en) 1989-12-22 1997-07-30 Applied Research Systems Ars Holding N.V. Endogenous gene expression modification with regulatory element by way of homologous recombination
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JP3149960B2 (ja) 1991-01-24 2001-03-26 財団法人化学及血清療法研究所 ヒト組織因子を定量する方法
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
JPH05244988A (ja) 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994005328A1 (en) 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
WO1996001653A1 (en) 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
JP4423680B2 (ja) 1995-06-07 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｒ−グラフト化抗組織因子抗体及びその使用
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
JPH09302000A (ja) 1996-05-16 1997-11-25 Chemo Sero Therapeut Res Inst 抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US20040229282A1 (en) 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
TR200101541T2 (tr) 1998-04-03 2002-06-21 Chugai Seiyaku Kabushiki Kaisha İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor.
NZ510488A (en) 1998-09-04 2003-07-25 Aventis Pasteur Immunotherapy for HPV DNA-positive cervical cancers with DNA constructs for the administration of HPV antigens to provide an immune response in a host
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
AU6375000A (en) 1999-07-29 2001-02-19 Medarex, Inc. Human monoclonal antibodies to her2/neu
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
AU5081401A (en) 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP1374896A4 (en) 2001-03-26 2005-04-06 Koji Suzuki MEANS TO IMPROVE THE FLUID CHARACTERISTICS OF BLOOD
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
NZ531211A (en) 2001-08-23 2007-04-27 Genmad As Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
AU2002361471A1 (en) 2001-08-30 2003-03-18 Mount Sinai School Of Medicine Of New York University Alternatively spliced circulating tissue factor
HUP0401658A2 (hu) 2001-10-02 2004-11-29 Novo Nordisk A/S Humán szöveti faktor ellenanyagok
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2002336920A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
MXPA04008061A (es) 2002-02-22 2005-06-20 Prophy Med Ab Uso de inhibidor o antagonista contra factor tisular.
UA85996C2 (ru) 2002-05-01 2009-03-25 Шеринг Акциенгезельшафт Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AU2003242506A1 (en) 2002-07-12 2004-02-02 Novo Nordisk A/S Tf antagonist
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003277832A1 (en) 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
WO2004041302A1 (en) 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
AU2003275948A1 (en) 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
ES2401136T3 (es) 2002-11-15 2013-04-17 Genmab A/S Anticuerpos monoclonales humanos contra CD25
JP4739763B2 (ja) 2002-12-16 2011-08-03 ゲンマブ エー／エス インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
EP1587549A2 (en) 2003-01-22 2005-10-26 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US20060034846A1 (en) 2003-04-14 2006-02-16 Mirella Ezban Use of TF antagonists
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
EP1633309A4 (en) 2003-05-30 2007-06-13 Centocor Inc METHOD FOR INHIBITING TUMOR GROWTH WITH ANTI-TISSUE FACTOR ANTIBODIES
WO2005000896A2 (en) 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
MXPA05013789A (es) 2003-06-19 2006-06-27 Tanox Inc Composiciones y metodos para tratar los desordenes relacionados con la coagulacion.
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
JP2007504167A (ja) 2003-08-29 2007-03-01 セントカー・インコーポレーテツド 抗組織因子抗体を用いる移植片の生存を向上する方法
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
PT1691837E (pt) 2003-12-10 2012-08-27 Medarex Inc Anticorpos ip-10 e suas utilizações
JP2007523099A (ja) 2004-02-20 2007-08-16 ノボ　ノルディスク　アクティーゼルスカブ 組み合わせ療法
WO2005118646A2 (en) 2004-04-26 2005-12-15 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
EP1945264A2 (en) 2005-10-21 2008-07-23 Genentech, Inc. Treatment for antiphospholipid-syndrome-related pregnancy complications
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007076091A2 (en) 2005-12-22 2007-07-05 Genentech, Inc. Treatment of viral infections using a tissue factor inhibitor
MX2008009956A (es) 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
LT2845866T (lt) * 2006-10-27 2017-07-10 Genentech, Inc. Antikūnai ir imunokonjugatai bei jų panaudojimas
AU2008216495A1 (en) * 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
CA2685698A1 (en) * 2007-04-30 2008-11-13 Centocor Ortho Biotech Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
EP2164873B2 (en) 2007-05-31 2018-09-12 Genmab A/S Stable igg4 antibodies
ES2433379T3 (es) 2007-08-01 2013-12-10 Syntarga B.V. Análogos de CC-1065 sustituidos y sus conjugados
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
US8889868B2 (en) 2008-11-03 2014-11-18 Syntarga Bv CC-1065 analogs and their conjugates
EP2358393A1 (en) * 2008-11-20 2011-08-24 F.Hoffmann-La Roche Ag Therapeutic protein formulations
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5172811B2 (ja) 2009-10-27 2013-03-27 株式会社ジェイエスピー 発泡性スチレン系樹脂粒子及び該樹脂粒子の製造方法、並びにスチレン系樹脂発泡粒子成形体
CA2802782C (en) 2010-06-15 2018-03-13 Genmab A/S Human antibody drug conjugates against tissue factor
JP5244988B1 (ja) 2012-02-20 2013-07-24 浜松ホトニクス株式会社 濃度測定装置および濃度測定方法
EP4420729A3 (en) * 2013-11-21 2024-10-30 Genmab A/S Antibody-drug conjugate formulation

Also Published As

Publication number Publication date
EA034675B1 (ru) 2020-03-05
ES2647388T3 (es) 2017-12-21
EA201300016A1 (ru) 2013-06-28
DK2582728T3 (da) 2017-11-27
FR25C1032I1 (fr) 2025-09-26
MX347893B (es) 2017-05-18
AU2011267106A1 (en) 2013-01-10
US20240294661A1 (en) 2024-09-05
EP2582728B1 (en) 2017-08-23
RS56599B1 (sr) 2018-02-28
CN111012921A (zh) 2020-04-17
FIC20253007I1 (fi) 2025-08-26
SMT201700547T1 (it) 2018-01-11
SI2582728T1 (en) 2018-01-31
LT2582728T (lt) 2017-12-11
CN106084053A (zh) 2016-11-09
US20160067349A1 (en) 2016-03-10
KR20130117751A (ko) 2013-10-28
BR112012031727A2 (pt) 2016-10-11
ME02919B (me) 2018-04-20
WO2011157741A2 (en) 2011-12-22
CY1119616T1 (el) 2018-04-04
NZ604718A (en) 2015-01-30
MX2012014552A (es) 2013-01-29
CN103119065B (zh) 2016-08-03
CN106084053B (zh) 2020-01-17
US20130101608A1 (en) 2013-04-25
WO2011157741A3 (en) 2012-03-08
LTPA2025527I1 (nl) 2025-08-11
NO2025033I1 (no) 2025-07-23
EP4434550A3 (en) 2025-02-26
HUS2500031I1 (hu) 2025-08-28
EP4434550A2 (en) 2024-09-25
CA2802782A1 (en) 2011-12-22
CA2802782C (en) 2018-03-13
HUE035599T2 (en) 2018-05-28
US9492565B2 (en) 2016-11-15
JP6055404B2 (ja) 2016-12-27
EP3281956A2 (en) 2018-02-14
PL2582728T3 (pl) 2018-01-31
AU2011267106B2 (en) 2015-05-14
NO2582728T3 (nl) 2018-01-20
US9168314B2 (en) 2015-10-27
KR101935058B1 (ko) 2019-01-03
EP3281956A3 (en) 2018-04-18
US20210395384A1 (en) 2021-12-23
US20190315880A1 (en) 2019-10-17
EP2582728A2 (en) 2013-04-24
PT2582728T (pt) 2017-11-23
JP2013532148A (ja) 2013-08-15
BR112012031727B1 (pt) 2022-03-29
US20170136130A1 (en) 2017-05-18
CN103119065A (zh) 2013-05-22
HRP20171789T1 (hr) 2017-12-29

Similar Documents

Publication Publication Date Title
NL301340I2 (nl) tisotumab vedotin
NO2022039I1 (no) Enfortumab vedotin
DK3225404T3 (da) Fluidpatron
EP2578585A4 (en) Purinone derivative
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
EP2568873A4 (en) VACUUM RETRACTOR
EP2529782A4 (en) INTRODUCER SLEEVE ASSEMBLY
EP2591235A4 (en) FUSION METAL WHEEL
DE112011104226A5 (de) Käfigmutter
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
EP2660110A4 (en) Wiper blade
DE112011102080A5 (de) Kupplungszentralausrücker
DE112011101226A5 (de) Linearwegmesssystem
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102010038420A8 (de) Reinigungungsvorrichtung
DE102011002623A8 (de) Ventilsteuerzeitversteller
EP2571003A4 (en) RISK CALCULATION APPARATUS
EP2646037A4 (en) INHIBITION OF HISTONES
DE112011102711A5 (de) Hydrostataktor
DK2448659T3 (da) Rotorskive
DK2447426T3 (da) Vaske-WC